September 2025

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry

J Eur Acad Dermatol Venereol 2025;39:1643–55 Doi: 10. 1111/ jdv. 20831

This study by Olivares-Guerrero et al. provides comparative safety data from a clinical practice point of view, potentially contributing to facilitate the drug selection process for clinicians. New biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars. Olivares-Guerrero et al. used data from the BIOBADADERM registry of AEs to analyse the long-term safety profile of systemic treatments, including biological agents as well as new small oral molecules approved for the treatment of moderate-to-severe PsO, using adalimumab and its biosimilars as comparators.

Keywords:

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry

J Eur Acad Dermatol Venereol 2025;39:1631–42 https:// doi. org/ 10. 1111/ jdv. 20828

This study by Lluch-Galcerá et al. provides valuable RWE to inform personalized clinical decision-making in the treatment of PsO. Authors evaluated the incidence of MACE associated with each systemic treatment used for patients with PsO and compared these rates to those observed with MTX.

Keywords:

August 2025

A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

Clin Exp Dermatol 2025;50:1786–1794 Doi: 10.1093/ced/llaf172

This study by Mortato et al. enhanced the limited safety data on guselkumab in patients with moderate-to-severe plaque psoriasis who have clinically relevant infectious and oncological comorbidities as well as concomitant heart disease. Authors assessed clinical outcomes and safety of guselkumab in a large cohort of patients with concomitant chronic infection, cancer or heart disease over a long follow-up period, addressing critical gaps in clinical evidence.

Keywords:

A real-world comparison of clinical effectiveness of upadacitinib, tumor necrosis factor inhibitors or interleukin-17 inhibitors in patients with axial spondyloarthritis after switching from an initial tumor necrosis factor inhibitor treatment

Rheumatol Ther 2025; Epub ahead of print doi: 10.1007/s40744-025-00786-2

Baraliakos et al. compared real-world effectiveness of upadacitinib, TNF inhibitors, or IL-17 inhibitors following inadequate response to an initial TNF inhibitor in patients with axSpA. Upadacitinib was associated with greater reductions in pain and fewer affected joints compared with switching to a second TNF inhibitor or IL-17 inhibitor.

Keywords:

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study

RMD Open 2025;11:e005806 doi: 10.1136/rmdopen-2025-005806

In this nationwide observational study, ixekuzumab was mainly used in patients with axSpA and PsA who had previously failed multiple b/tsDMARDs, including other IL-17 inhibitors. Although prior IL-17 treatment was associated with increased risk of withdrawal in both groups, the relatively high retention rates and improvements in all disease outcomes suggest ixekizumab as a viable option for challenging patients with multiple b/tsDMARD failures.

Keywords:

Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis

Biomedicines 2025;13:2089 Doi: 10.3390/biomedicines13092089

This study by Lee et al. is the first to evaluate the association between adalimumab dosing intervals and uveitis recurrence in patients with AS. Authors investigated whether extending the dosing interval of adalimumab influences the recurrence of uveitis in AS patients with a history of AU who are on adalimumab therapy.

Keywords:

Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)

Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559

In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.

Keywords:

Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort

J Dermatol 2025 Doi: 10.1111/1346-8138.17906 Epub ahead of print

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.

Keywords:

July 2025

Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers

J Am Acad Dermatol 2025;93:104–14 doi: 10.1016/j.jaad.2025.03.016

In this nationwide study of Swedish PsO and PsA patients treated with ustekinumab, etanercept, adalimumab, or secukinumab, spanning more than 10 years, the overall risk of MACE was low across treatment groups. There was no meaningful difference in risk of MACE between ustekinumab and the other treatments.

Keywords:

Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Front Immunol 2025;16:1586792 doi: 10.3389/fimmu.2025.1586792

UPA has shown effectiveness in treating IMIDs like RA, axSpA, PsA, CD, and UC. Chai et al. evaluated evidence from a synthesis of RCTs and provided insights that may guide clinical decision-making and improve treatment outcomes for IMIDs. UPA effectively alleviated symptoms, reduced disease activity, and showed notable benefits in improving quality of life.

Keywords: